Trial reportJAMA internal medicine2023
Deprescribing Medications Among Older Adults From End of Hospitalization Through Postacute Care: A Shed-MEDS Randomized Clinical Trial.
Trial report in JAMA internal medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02979353 (A Randomized Controlled Trial to Deprescribe for Older Patients With Polypharmacy Transferred From the Hospital to Skilled Nursing Facilities), which is not on this map. Cited by 47 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized Controlled Trial to Deprescribe for Older Patients With Polypharmacy Transferred From the Hospital to Skilled Nursing Facilities
Who cites it
47 citing papers in PubMed, 4 syntheses or guidelines pooled it, 75 citations in OpenAlex.
- Bridging the Gap: Systematic Review of Strategies to Facilitate Post-Discharge Continuity of In-Hospital Medication Changes in Older Adults.Drugs & aging · 2026Pooled it
- Criteria to Report Adverse Drug Withdrawal Events in Clinical Trials: A Systematic Review.Journal of the American Geriatrics Society · 2025Pooled it
- Medication Use Quality and Safety in Older Adults: 2023 Update.Journal of the American Geriatrics Society · 2025Pooled it
- Systematic Review and Meta-analysis of Interventions to Reduce Adverse Drug Reactions in Older Adults: An Update.Drugs & aging · 2023Pooled it
- Comparing Fourteen Behavioral Science Electronic Health Record Deprescribing Tools in Older Adults: NUDGE-EHR Adaptive Trial.Journal of the American Geriatrics Society · 2025Trial
- Effect of antihypertensive deprescribing on hospitalisation and mortality: long-term follow-up of the OPTiMISE randomised controlled trial.The lancet. Healthy longevity · 2024Trial
- Medication Optimization Protocol Efficacy for Geriatric Inpatients: A Randomized Clinical Trial.JAMA network open · 2024Trial
- Pharmacist-led telehealth deprescribing for people living with dementia and polypharmacy in primary care: A pilot study.Journal of the American Geriatrics Society · 2024Trial
- Trial
- Why do older adults decline participation in research? Results from two deprescribing clinical trials.Trials · 2023Trial
- Assessing Associations of Three Types of Higher-Risk Medication Use and Mortality in Older Adults.Journal of the American Geriatrics Society · 2026Article
- Potentially Inappropriate Medication Use Following Hospital Discharge Among Medicare Beneficiaries.The American journal of managed care · 2026Observational
- Deprescribing Decisions in Swiss Primary Care: Low Concordance Between General Practitioners and Older Adults.Journal of general internal medicine · 2026Article
- Restarting Medications After Deprescribing in Adults Discharged From Hospital to Skilled Nursing.JAMA network open · 2026Article
- Review
- Applying the Age-Friendly Health Systems Framework to Promote Adoption and Sustainability of Interventions for Older Adults in the Intensive Care Unit.Journal of gerontological nursing · 2026Review
- Willingness to Participate in Deprescribing Trials: A Survey of Older Adults in Two Countries.Journal of the American Geriatrics Society · 2026Article
- Medication review in older adults at hospital discharge: an analysis of data from the IATROPREV study.European geriatric medicine · 2026Observational
- Pre- and Postoperative Prescription of Opioids and Benzodiazepines in the US.Journal of the American College of Surgeons · 2026Article
- Glycated hemoglobin (A1c) values and antidiabetic treatment deprescription in hospitalized nonagenarians with type 2 diabetes.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
Importance: Deprescribing is a promising approach to addressing the burden of polypharmacy. Few studies have initiated comprehensive deprescribing in the hospital setting among older patients requiring ongoing care in a postacute care (PAC) facility. Objective: To evaluate the efficacy of a patient-centered deprescribing intervention among hospitalized older adults transitioning or being discharged to a PAC facility. Design, Setting, and Participants: This randomized clinical trial of the Shed-MEDS (Best Possible Medication History, Evaluate, Deprescribing Recommendations, and Synthesis) deprescribing intervention was conducted between March 2016 and October 2020. Patients who were admitted to an academic medical center and discharged to 1 of 22 PAC facilities affiliated with the medical center were recruited. Patients who were 50 years or older and had 5 or more prehospital medications were enrolled and randomized 1:1 to the intervention group or control group. Patients who were non-English speaking, were unhoused, were long-stay residents of nursing homes, or had less than 6 months of life expectancy were excluded. An intention-to-treat approach was used. Interventions: The intervention group received the Shed-MEDS intervention, which consisted of a pharmacist- or nurse practitioner-led comprehensive medication review, patient or surrogate-approved deprescribing recommendations, and deprescribing actions that were initiated in the hospital and continued throughout the PAC facility stay. The control group received usual care at the hospital and PAC facility. Main Outcomes and Measures: The primary outcome was the total medication count at hospital discharge and PAC facility discharge, with follow-up assessments during the 90-day period after PAC facility discharge. Secondary outcomes included the total number of potentially inappropriate medications at each time point, the Drug Burden Index, and adverse events. Results: A total of 372 participants (mean [SD] age, 76.2 [10.7] years; 229 females [62%]) were randomized to the intervention or control groups. Of these participants, 284 were included in the intention-to-treat analysis (142 in the intervention group and 142 in the control group). Overall, there was a statistically significant treatment effect, with patients in the intervention group taking a mean of 14% fewer medications at PAC facility discharge (mean ratio, 0.86; 95% CI, 0.80-0.93; P < .001) and 15% fewer medications at the 90-day follow-up (mean ratio, 0.85; 95% CI, 0.78-0.92; P < .001) compared with the control group. The intervention additionally reduced patient exposure to potentially inappropriate medications and Drug Burden Index. Adverse drug event rates were similar between the intervention and control groups (hazard ratio, 0.83; 95% CI, 0.52-1.30). Conclusions and Relevance: Results of this trial showed that the Shed-MEDS patient-centered deprescribing intervention was safe and effective in reducing the total medication burden at PAC facility discharge and 90 days after discharge. Future studies are needed to examine the effect of this intervention on patient-reported and long-term clinical outcomes. Trial Registration: ClinicalTrials.gov Identifier: NCT02979353.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.